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Summary
Background Women born around 1940 in countries such as the UK and USA were the ﬁ rst generation in which many 
smoked substantial numbers of cigarettes throughout adult life. Hence, only in the 21st century can we observe 
directly the full eﬀ ects of prolonged smoking, and of prolonged cessation, on mortality among women in the UK.
Methods For this prospective study, 1·3 million UK women were recruited in 1996–2001 and resurveyed postally about 
3 and 8 years later. All were followed to Jan 1, 2011, through national mortality records (mean 12 woman-years, SD 2). 
Participants were asked at entry whether they were current or ex-smokers, and how many cigarettes they currently 
smoked. Those who were ex-smokers at both entry and the 3-year resurvey and had stopped before the age of 55 years 
were categorised by the age they had stopped smoking. We used Cox regression models to obtain adjusted relative risks 
that compared categories of smokers or ex-smokers with otherwise similar never-smokers.
Findings After excluding 0·1 million women with previous disease, 1·2 million women remained, with median birth year 
1943 (IQR 1938–46) and age 55 years (IQR 52–60). Overall, 6% (66 489/1 180 652) died, at mean age 65 years (SD 6). At 
baseline, 20% (232 461) were current smokers, 28% (328 417) were ex-smokers, and 52% (619 774) were never-smokers. 
For 12-year mortality, those smoking at baseline had a mortality rate ratio of 2·76 (95% CI 2·71–2·81) compared with 
never-smokers, even though 44% (37 240/85 256) of the baseline smokers who responded to the 8-year resurvey had by 
then stopped smoking. Mortality was tripled, largely irrespective of age, in those still smoking at the 3-year resurvey (rate 
ratio 2·97, 2·88–3·07). Even for women smoking fewer than ten cigarettes per day at baseline, 12-year mortality was 
doubled (rate ratio 1·98, 1·91–2·04). Of the 30 most common causes of death, 23 were increased signiﬁ cantly in smokers; 
for lung cancer, the rate ratio was 21·4 (19·7–23·2). The excess mortality among smokers (in comparison with never-
smokers) was mainly from diseases that, like lung cancer, can be caused by smoking. Among ex-smokers who had 
stopped permanently at ages 25–34 years or at ages 35–44 years, the respective relative risks were 1·05 (95% CI 1·00–1·11) 
and 1·20 (1·14–1·26) for all-cause mortality and 1·84 (1·45–2·34) and 3·34 (2·76–4·03) for lung cancer mortality. Thus, 
although some excess mortality remains among these long-term ex-smokers, it is only 3% and 10% of the excess mortality 
among continuing smokers. If combined with 2010 UK national death rates, tripled mortality rates among smokers 
indicate 53% of smokers and 22% of never-smokers dying before age 80 years, and an 11-year lifespan diﬀ erence.
Interpretation Among UK women, two-thirds of all deaths of smokers in their 50s, 60s, and 70s are caused by 
smoking; smokers lose at least 10 years of lifespan. Although the hazards of smoking until age 40 years and then 
stopping are substantial, the hazards of continuing are ten times greater. Stopping before age 40 years (and 
preferably well before age 40 years) avoids more than 90% of the excess mortality caused by continuing smoking; 
stopping before age 30 years avoids more than 97% of it.
Funding Cancer Research UK, Medical Research Council.
Introduction
Smoking, mainly of cigarettes, remains the leading 
preventable cause of death in countries such as the 
UK and USA, despite declines in smoking prevalence 
and in the machine-measured tar yields of manufactured 
cigarettes.1–3 Among smokers who are now in their 60s, 
the excess hazards depend strongly not only on their 
recent smoking habits, but also on their smoking habits 
in early adult life, more than 40 years ago.4 Many men 
born during the ﬁ rst quarter of the 20th century started 
smoking substantial numbers of cigarettes from a young 
age, so the full hazards in middle and old age have 
already been seen among men,5–7 but few women began 
smoking until the second quarter of the century. 
Smoking prevalence in young women did not peak until 
the 1960s,8 so previous studies of women might have 
considerably underestimated the full even tual risks of 
smoking. Direct measurements of the excess hazards for 
women who smoke throughout adult life therefore 
require studies of mortality during the 21st century 
among women born after the ﬁ rst quarter of the 
20th century in countries such as the UK or USA, rather 
than studies of mortality decades earlier, or of popu-
lations in which cigarette smoking became widespread 
even more recently.
The hazards of smoking for women in the USA during 
the late 20th century have been reported by several 
reliable studies, including two large prospective ones: the 
ACS Cancer Prevention Study II (CPS-II)7 of adults 
recruited in the 1980s, and the Nurses’ Health Study9,10 of 
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women recruited in the 1970s. We report the hazards of 
smoking and the beneﬁ ts of having stopped at various 
ages in a prospective study of a million women in the 
UK, based on 21st century mortality rates.
Methods
Study design and participants
In 1996–2001, participants were recruited into the 
Million Women Study through the National Health 
Service Breast Screening Programme (NHSBSP), sign-
ing consent and completing a questionnaire about 
lifestyle, medical history, and sociodemographic factors, 
and were resurveyed postally about 3 and 8 years later. 
Study participants had unique NHS numbers that link 
to the NHS Central Register. Dates of any deaths were 
routinely notiﬁ ed to us, with underlying causes already 
coded to the International Classiﬁ cation of Diseases, 
ICD-10.11 All women, including those who did not 
respond to the resurveys, were followed up for mortality 
to Jan 1, 2011 (mean 12 woman-years, SD 2) through UK 
national records.
Million Women Study methods are described else-
where,12 and questionnaires are available online. Study 
participants signed consent to follow-up. Ethics approval 
was obtained from Oxford and Anglia Multicentre 
Research Ethics Committee.
Procedures
At entry, women were asked if they were a current or 
ex-smoker, and how many cigarettes they now smoked 
(in categories of amount smoked: none, <5, 5–9, 10–14, 
15–19, 20–24, or ≥25 cigarettes per day; table). These 
questions were used to deﬁ ne baseline smoking status 
for analyses of 12-year mortality, although in the UK 
almost half the women who were smokers in the 
1990s gave up by 2010.13 At the 3-year resurvey, women 
were asked at what ages they had ﬁ rst smoked regularly 
and had stopped. Those who were ex-smokers at both 
entry and the 3-year resurvey and had stopped before the 
age of 55 years were categorised by the age they stopped 
smoking (<25, 25–34, 35–44, or 45–54 years). We did not 
analyse results by pack-years, since having smoked ten 
cigarettes a day for 40 years could produce at age 60 years 
a risk of lung cancer vastly greater than that from having 
smoked 20 cigarettes a day for the past 20 years.4
To assess the causal eﬀ ects of continued smoking and 
of cessation at various ages (while avoiding the biasing 
eﬀ ects of reverse causality, whereby disease causes 
cessation), women were excluded if at baseline they had 
already had any cancer registered (other than non-
melanoma skin cancer), or reported any history of heart 
disease, stroke, or current respiratory disease treatment.
The remainder contributed woman-years until Jan 1, 
2011, or death, or emigration, irrespective of whether 
they responded to subsequent surveys. National mortality 
statistics provide virtually complete follow-up of UK 
deaths (including deaths of UK citizens temporarily 
abroad) and departure dates for the few who leave 
permanently (1·4% [16 275/1 180 652], who were included 
in our analyses until their last date of follow-up). The 
main analyses of current smokers versus never-smokers 
related smoking at baseline to 12-year risk, even though 
many smokers stopped during follow-up, thereby 
reducing their risk. Analyses of the residual hazards in 
those who had stopped smoking at various ages were 
restricted to those not smoking at recruitment and still 
not smoking at the 3-year resurvey. We excluded women 
who stopped smoking after the age of 55 years, so as to 
avoid including substantial numbers of women who had 
stopped recently because of ill health. Analyses of the 
eﬀ ects among smokers by the age they ﬁ rst smoked 
regularly were restricted to those smoking both at 
recruitment and at the 3-year resurvey.
Statistical analysis
We used Cox regression models (with attained age as the 
underlying time variable) to obtain adjusted relative risks 
that compared categories of smokers or ex-smokers with 
never-smokers (treated as a ﬁ xed reference group). 
Adjustment was by geographical region (ten UK cancer 
registry regions), age (in single years) and other variables 
(in categories) such as body-mass index (<20, 20–24·9, 
25–29·9, or ≥30 kg/m²), socioeconomic status (quintiles 
of 1991 Townsend deprivation index for area of residence 
at recruitment),14 current alcohol intake (none, <2, 2–7, 
8–14, or ≥15 units per week), weekly strenuous physical 
For the questionnaires see 
http://www.millionwomenstudy.
org
Never smoker 
at recruitment
Ex-smoker at 
recruitment
Current smoker at recruitment, by cigarettes per day
<10 10–19 ≥20 All amounts
Number of women 619 774 328 417 58 957 116 122 57 382 232 461
Percentage of current smokers when 
resurveyed
<0·1% 
(223/424 277)
2·2% 
(4756/217 248)
65·2% 
(19 417/29 773)
79·4% 
(44 401/55 953)
83·6% 
(23 229/27 795)
76·7% 
(87 047/113 521)
Age at which participant ﬁ rst started to 
smoke regularly, years
NA 18·7 (4·4) 20·2 (6·5) 18·9 (5·1) 18·1 (4·5) 19·1 (5·4)
Cigarettes smoked per day at resurvey NA NA* 8·0 (4·4) 14·8 (4·6) 22·2 (6·6) 15·2 (7·2)
Data are % of women (n/N), or mean (SD). NA=not applicable. *Mean consumption had been 13·5 (SD 9·2) cigarettes per day when these women last smoked.  
Table: Smoking patterns at the postal resurvey about 3 years after recruitment, by smoking status reported at recruitment
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activity (rarely or more often), height (<160, 160–164·9, or 
≥165 cm), oral contraceptive use (never or ever), 
menopausal status (pre-menopausal, peri-meno pausal, 
or post-menopausal), and menopausal hormone therapy 
use (never or ever). For every variable, missing values 
formed a separate category. We excluded women with 
bilateral oophorectomy at baseline from ovarian cancer 
analyses, and those with hysterectomy from endometrial 
cancer analyses.
When plotting relative risks by amount smoked, we 
deﬁ ned the categories and calculated the risks by 
consumption reported at recruitment. We then plotted 
these risks against the mean number of cigarettes 
reported at the 3-year resurvey by those still smoking, 
taken as an estimate of long-term mean consumption 
before the study started among all in that category.
To assess the relevance of the age at which participants 
ﬁ rst started smoking regularly among those who smoke 
similar amounts, we adjusted relative risks for cigarettes 
smoked per day (by taking a weighted average of the log 
relative risks within each category of amount smoked, 
weighted by the proportion of women in each category).
As smoking correlates with drinking, we did 
sensitivity analyses for causes of death where alcohol is 
a known risk factor such as liver disease, external 
causes (mainly accidents and suicide), and cancers of 
the upper aero-digestive tract, liver, or breast. These 
sensitivity analyses were restricted to women who 
reported drinking less than three units per week (UK 
unit: 10 mL of alcohol).
Relative risks are plotted as squares. In ﬁ gure 1, the 
area of each square is inversely proportional to the 
variance of the log risk in each separate category of 
amount smoked or age at which par ticipant began 
smoking (indicating the informativeness of that one 
category alone).15 In ﬁ gure 2, it is proportional to the 
variance of the log relative risk (indicating the 
informativeness of the comparison between two 
categories). Corresponding 95% CIs are plotted as lines. 
The text cites only con ventional 95% CIs that compare 
two categories. We used Stata version 12.1 for calculations. 
To illustrate the absolute eﬀ ects of our relative risk 
estimate, we apply it to a hypothetical population where 
non-smokers and smokers each have an appropriate 
fraction of the UK 2010 female mortality rates.16
Role of funding sources
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all the 
data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
1 311 943 women aged 50–69 years were recruited and 
answered questions on smoking status. Women with 
previous disease at baseline were excluded, of whom 
58 730 reported cancer (other than non-melanoma 
skin cancer), 57 751 reported history of heart disease, 
10 984 reported stroke, and 3826 women were currently 
under treatment for respiratory disease.
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Figure 1: All-cause mortality, current versus never-smoker
(A) 12-year relative risk by amount smoked (at recruitment). (B) 9-year relative 
risk by the age at which women ﬁ rst began smoking regularly (as reported at the 
3-year postal resurvey). For each category, the area of the square is inversely 
proportional to the variance of the category-speciﬁ c log risk (which also 
determines the CI).
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After exclusion of these previous disease categories, 
1 180 652 women remained. They were on average born 
in 1943 (IQR 1938–1946), recruited in 1998 (range 
1996–2001) at age 55 years (IQR 52–60), and followed for 
12 years (SD 2) to Jan 1, 2011, during which time 6% 
(66 489) died, at mean age 65 (SD 6) years.
At baseline, 20% (232 461) of women were current 
smokers, 28% (328 417) were ex-smokers, and 52% 
(619 774) were never-smokers. The appendix (p 3) shows 
characteristics of the participants; the main diﬀ erences 
were that smokers were more likely than non-smokers 
to live in deprived areas, drink more than 14 units of 
alcohol weekly, and avoid strenuous exercise. Analyses 
of the eﬀ ects of smoking were, therefore, adjusted for 
these and other diﬀ erences. Exposure to second-hand 
smoke from a partner was uncommon in never-
smokers, with only 13% (44 031/341 232) of never-
smokers reporting it at the 3-year resurvey. Random 
samples of participants were invited 9 years after 
baseline to give blood or for anthropometry. Comparing 
those who had been current smokers, ex-smokers, and 
never-smokers at baseline, we noted no substantial 
diﬀ erences in lipid proﬁ le, blood pressure, or measured 
body-mass index (appendix pp 3–4).
The table describes smoking patterns at the ﬁ rst postal 
resurvey, at which 49% (113 521/232 461) of current 
smokers, 66% (217 248/328 417) of ex-smokers, and 68% 
(424 277/619 774) of never-smokers at baseline, replied and 
answered questions on smoking status. The consistency 
of the replies shows that there was little misclassiﬁ cation 
of never-smokers and ex-smokers, and that few 
ex-smokers restarted (table). But, of the current smokers 
at baseline who replied at the 3-year resurvey, 23% 
(26 474/113 521) had stopped smoking, as had 44% 
(37 240/85 256) at the 8-year resurvey, with cessation more 
common among lighter smokers (appendix p 3). Those 
still smoking at the 3-year resurvey reported on average 
having started at age 19 years (SD 5) and currently 
smoking 15 cigarettes per day (SD 7).
All study participants, including responders and non-
responders to resurveys, were followed for mortality. 
During the 12-year mortality follow-up, those who had 
been current smokers at baseline had almost three times 
the overall mortality rate of never-smokers (adjusted 
mortality rate ratio of 2·76, 95% CI 2·71–2·81), even 
though within just a few years of recruitment many had 
stopped smoking, thereby reducing their risk. Had we 
inappropriately included women with previous disease at 
baseline, the relative risk would have been 2·62 
(2·58–2·67). Those who were still smoking at the 3-year 
resurvey had a mortality rate ratio of 2·97 (2·88–3·07) 
during the remainder of the study, even though some 
later stopped smoking. These analyses were fully ad-
justed for the measures available to us of socioeconomic 
status, alcohol intake, and inactivity, thereby somewhat 
attenuating them (sensitivity analyses in appendix p 5).
The risks in smokers increased steeply with the amount 
smoked and happened to fall nearly on a straight line 
(ﬁ gure 1A). Even those smoking fewer than ten cigarettes 
per day at baseline had double the overall mortality rate 
of never-smokers. Smoking was cat egorised as shown in 
the table, which suggests that when those in the lowest 
category were smoking, they consumed about eight 
cigarettes per day. At the individual level it is unclear how 
much past and current consumption diﬀ ered, but, on 
average, the amount consumed per smoker seemed to 
have changed little during adult life (14 cigarettes per day 
[SD 7] at age 20 years and 14 cigarettes per day [SD 7] 
currently, in a subsample of 7437 women who responded 
to a resurvey about 12 years after study entry, and were 
smokers then and at age 20 years). 
The age at which women had ﬁ rst started smoking 
regularly aﬀ ected overall mortality decades later. Those 
who had started at about age 15 years were at greater risk 
than those who had started only 4 years later (ﬁ gure 1B); 
10 72 3 4 5 6
Chronic lung disease (J40–44)                          121  35·3 (29·2–42·5)
Cancer of lung (C34)                                   698  21·4 (19·7–23·2)
Aortic aneurysm (I71)                                  164  6·32 (5·17–7·71)
Intestinal ischaemia (K55)                             91  5·58 (4·27–7·29)
Cancer of mouth, pharynx, larynx,
nasal cavity, or sinuses (C00–14,30–32)
91  4·83 (3·72–6·29)
Coronary heart disease (I21–25)                        1732  4·47 (4·19–4·77)
Cirrhosis or alcoholic liver (K70,74)                  256  3·35 (2·84–3·94)
Cancer of bladder (C67)                                156  3·29 (2·61–4·15)
Cancer of oesophagus (C15)                             397  3·10 (2·68–3·58)
Pneumonia (J12–18)                                     408  3·09 (2·68–3·56)
Cerebrovascular disease (I60–69)                       1458  3·06 (2·83–3·31)
Cancer of pancreas (C25)                               1082  2·30 (2·08–2·53)
Cancer of kidney (C64)                                 360  2·10 (1·77–2·50)
Cancer of stomach (C16)                                329  2·00 (1·67–2·39)
Diabetes (E10–14)                                      192  1·81 (1·43–2·31)
External causes* (V01–Y98)                             677  1·76 (1·56–2·00)
Pulmonary fibrosis (J84·1)                             162  1·53 (1·16–2·01)
Cancer of liver (C22)                                  319  1·52 (1·24–1·85)
Venous thromboembolism (I26,80–82)                     669  1·46 (1·27–1·68)
Leukaemia (C91–95)                                     416  1·34 (1·11–1·62)
Motor neurone disease (G12·2)                          374  1·29 (1·06–1·58)
Cancer of large intestine (C18–20)                     1671  1·25 (1·14–1·37)
Non–Hodgkin lymphoma (C82–85)                          561  1·16 (0·98–1·37)
Cancer of breast (C50)                                 2295  1·13 (1·04–1·22)
Brain tumours (C71,D43)                                787  1·08 (0·94–1·25)
Cancer of ovary (C56)                                  1953  1·04 (0·95–1·15)
Multiple myeloma (C90)                                 385  1·02 (0·82–1·27)
Alzheimer's and dementia (F03,G30)                     400  1·01 (0·82–1·24)
Melanoma (C43)                                         220  0·99 (0·75–1·31)
Cancer of endometrium (C54)                            393  0·75 (0·58–0·95)
RR (95% CI)
1789  
5633  
330  
183  
204  
2726  
478  
178  
450  
494  
1528  
809  
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247  
122  
487  
88  
171  
327  
176  
154  
685  
214  
912  
284  
663  
120  
129  
73  
84  
Current 
smoker
Never 
smoker
Number of deaths
Figure 2: 30 most common speciﬁ c causes of death (ICD-10): 12-year relative risk, current versus never-smoker
RR=relative risk. ICD=International Classiﬁ cation of Diseases. *Suicide (ICD-10 X60–64,Y10–34): RR 1·40 (1·12–1·75); 
transport accident (V01–99): 0·85 (0·60–1·21); and other external: 2·51 (2·11–2·99). The area of each square is 
inversely proportional to the variance of the log relative risk (vs never-smokers), which also determines the CI. 
See Online for appendix
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this eﬀ ect of age ﬁ rst started was more extreme for lung 
cancer than for overall mortality (appendix p 6).
Of the 30 most common underlying causes, or groups 
of causes, of death, many were neoplastic, but many were 
vascular or respiratory (ﬁ gure 2). For 23 of these 
30 causes, 12-year mortality rates were signiﬁ cantly 
higher in smokers than in never-smokers; the only cause 
signiﬁ cantly lower in smokers was, as expected,17 endo-
metrial cancer (ﬁ gure 2). The most extreme risk ratios 
were for chronic lung disease (risk ratio 35·3) and lung 
cancer (21·4), with, respectively, 1789 and 5633 deaths 
among current smokers. Excluding the ﬁ rst 3 years of 
follow-up did not materially alter any of these 30 risk 
ratios (appendix p 7).
For most of the 23 smoking-associated causes, there was 
a signiﬁ cant trend in risk among current smokers with 
amount smoked (appendix p 8). The four main diseases in 
smokers were chronic lung disease, lung cancer, heart 
disease, and stroke, which can all be caused by smoking.4–7 
For these, ﬁ gure 3 shows mortality rate ratios by amount 
smoked. Even women in the lowest category of amount 
smoked had, compared with never-smokers, substantial 
excess mortality from all four conditions.
Particularly for chronic lung disease, which has a long 
natural history, the lowest smoking category (and the 
recent ex-smokers) could include some who used to 
smoke more but cut down their consumption (or 
stopped) because of early eﬀ ects of the disease that would 
eventually cause death. To limit such biases, our analyses 
exclude women who reported at baseline any current 
treatment for respiratory disease, or any history of cancer, 
heart disease or stroke.
The appendix (p 9) shows the mortality ratios (current 
smokers versus never-smokers) for the same four main 
diseases at diﬀ erent ages. Vascular mortality rate ratios 
decreased steeply with age. For coronary heart disease, 
they were 6·66 (95% CI 5·60–7·93) at age 50–59 years, 
4·79 (4·40–5·22) at age 60–69 years, and 3·30 (2·92–3·73) 
at somewhat older ages (ages 70+ years, where mean age 
of those who died was 73 years). For stroke, they were 3·90 
(3·24–4·70) at age 50–59 years, 3·28 (2·94–3·65) at age 
60–69 years, and 2·43 (2·11–2·79) at somewhat older ages. 
For overall mor tality, however, the current smoker versus 
never-smoker mortality rate ratio varied little with age.
All results were adjusted by alcohol intake, but for 
causes for which alcohol is a known risk factor, we did 
additional sensitivity analyses among women who did 
not drink alcohol or consumed less than three units of 
alcohol per week. Although this restriction weakened 
some of these associations, all except that for breast 
cancer remained signiﬁ cant. The changes in the rate 
ratios were: from 4·83 to 3·76 (95% CI 2·65–5·31) for 
cancer of the mouth, pharynx, larynx, nasal cavity, or 
sinuses; from 3·35 to 3·37 (2·58–4·41) for cirrhosis and 
alcoholic liver disease; from 3·10 to 2·74 (2·27–3·30) 
for oesophagus cancer; from 1·76 to 1·60 (1·36–1·90) 
for external causes; from 1·52 to 1·43 (1·11–1·85) for 
liver cancer; and from 1·13 to 1·06 (0·95–1·18) for 
breast cancer.
Age at stopping smoking was ﬁ rst sought at the 3-year 
resurvey. At that resurvey, those who were still current 
smokers reported consuming on average 15·2 cigarettes 
per day, and during the remainder of the study had 
relative risks of 3·0 (95% CI 2·9–3·1) for overall 
mortality and 24·0 (21·3–27·1) for lung cancer mortality. 
Women who had stopped at ages under 25, 25–34, 
35–44, and 45–54 years (ie, at around ages 20, 30, 40, or 
50 years, respectively) had on average started at ages 17, 
18, 19, and 19 years and smoked 9·4, 12·5, 14·6, and 
15·5 cigarettes per day, so those who had stopped at 
ages 35–54 previously smoked from the same age and as 
many cigarettes per day as the continuing smokers.  
We assessed the residual hazard in later middle age in 
women who had stopped smoking in these four age 
ranges; ﬁ gure 4 gives ex-smoker versus never-smoker 
mortality ratios for overall mortality and lung cancer 
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Figure 3: 12-year relative risk, current smoker versus never-smoker, by amount smoked
(A) Chronic lung disease. (B) Cancer of the lung. (C) Coronary heart disease. (D) Cerebrovascular disease. For each category, the area of the square is inversely proportional to the variance of the 
category-speciﬁ c log risk (which also determines the CI).
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mortality; the appendix (p 10) gives the same for chronic 
lung disease, heart disease, and stroke.
Women who had stopped at ages 45–54 (mean 49) years 
were, like other women, mainly in their 60s during 
follow-up, at which time they still had substantially higher 
overall and lung cancer mortality rates than never-
smokers: relative risk 1·56 (95% CI 1·49–1·64) for overall 
mortality and 5·91 (5·01–6·97) for lung cancer mortality. 
Nevertheless, even the upper limit for this excess overall 
mortality (compared with never-smokers) was only about 
a third that of continuing smokers, so they avoided at 
least two-thirds of the excess mortality among smokers 
late in middle age.
Women who had stopped at ages 35–44 (mean 39) 
years also still had, 20 or 30 years later, higher overall 
mortality and lung cancer mortality than never-smokers. 
Their relative risk was 1·20 (95% CI 1·14–1·26) for 
overall mortality and 3·34 (2·76–4·03) for lung cancer 
mortality, both signiﬁ cantly increased (p<0·0001). 
Although these are not small residual risks, these ex-
smokers did avoid about 90% of the excess lung cancer 
mortality and excess overall mortality among continuing 
smokers. The appendix shows, likewise, that for chronic 
lung disease, coronary heart disease, and stroke, about 
90% of the excess risk was avoided by stopping at around 
age 40 years (and more by stopping earlier).
Women who had stopped at ages 25–34 (mean 29) 
years still had, decades later, measurably higher lung 
cancer mortality than did never-smokers: 86 deaths due 
to lung cancer were recorded among them as against 
about 46 predicted from never-smoker rates, relative risk 
1·84 (1·45–2·34), p<0·0001. They also had slightly higher 
overall mortality, relative risk 1·05 (1·00–1·11), p=0·05. 
They avoided, however, about 97% of the excess lung 
cancer mortality in continuing smokers, and seemed 
also to avoid about 97% of the excess overall mortality.
Finally, few women in this generation stopped smoking 
before age 25 years, so direct estimates of whatever small 
excess risks remained in later life are not statistically 
reliable. Those who did so had on average been light 
smokers who had stopped at mean age 22 years. They 
had a slight excess risk of lung cancer in later life, but 
this was based on only 24 deaths due to lung cancer 
observed as against about 15 predicted, so it is not 
statistically trustworthy: relative risk 1·56 (1·03–2·37), 
p=0·04. Their relative risk for overall mortality was 1·01 
(0·92–1·11). These conﬁ dence limits are uninformatively 
wide, given the narrower conﬁ dence limits already seen 
for the residual hazard in those who smoked substantial 
num bers and stopped smoking at ages 25–34 years.
Discussion
The excess mortality among smokers was chieﬂ y from 
diseases that are known to be aﬀ ected by smoking, such as 
lung cancer, chronic lung disease, heart disease, stroke, 
and various other neoplastic, respiratory, or vascular 
conditions.18 Moreover, results from randomly invited 
subsamples showed little diﬀ erence between smokers and 
others in potential confounding factors such as adiposity, 
blood pressure, or lipid proﬁ le. There were diﬀ erences 
between smokers and non-smokers in factors such as 
alcohol intake, physical activity, and socio economic status, 
but these were adjusted for (attenu at ing only slightly the 
hazards among smokers). Thus, although some of the 
associations of smoking (eg, with suicide or the fatal eﬀ ects 
of alcohol) might be partly or wholly non-causal, the large 
majority of the excess overall mortality among smokers is 
Age at stopping
(mean), years
Number of deaths
RR (95% CI)
20
<25 (22)
481
1·01
(0·92–1·11)
30
25–34 (29)
1523
1·05
(1·00–1·11)
40
35–44 (39)
1814
1·20
(1·14–1·26)
50
45–54 (49)
2095
1·56
(1·49–1·64)
0
1
2
3
4
Re
la
tiv
e 
ris
k 
(9
5%
 C
I)
A All–cause mortality
1·01 1·05
1·20
1·56
Age at stopping
(mean), years
Number of deaths
RR (95% CI)
20
<25 (22)
24
1·56
(1·03–2·37)
30
25–34 (29)
86
1·84
(1·45–2·34)
40
35–44 (39)
159
3·34
(2·76–4·03)
50
45–54 (49)
243
5·91
(5·01–6·97)
Age at stopping (years)
0
5
10
15
20
25
30
Re
la
tiv
e 
ris
k 
(9
5%
 C
I)
B Cancer of the lung
Never
smokers
Current
smokers
Current
smokers
Never
smokers
 1·56  1·84
 3·34
 5·91
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actually caused by smoking (ie, made more probable 
among otherwise similar people of the same age).
The purpose of the present analyses has been to help 
predict the eventual causal eﬀ ects of prolonged cigarette 
smoking on female mortality in many diﬀ erent countries, 
not just the UK. For assessment of smoker versus 
non-smoker relative risks of death from particular 
diseases, the fact that smokers were somewhat under-
represented in comparison with the general UK 
population (as the large majority of these women had 
been screened for breast cancer at entry, and all had 
chosen to participate in the present study) was not an 
important limitation, nor was the exclusion of women 
with various previous diseases. Although the relative 
risks for the eﬀ ects of prolonged smoking on particular 
diseases cannot be generalised exactly to populations 
with very diﬀ erent background rates of those diseases, 
they should be approximately generalisable to many 
(though not all) countries where women smoke.
For several of the diseases caused by smoking, and for 
all-cause mortality, the proportional excess risk in 
smokers was more marked than in many previous 
studies,17–19 but recently updated analyses of 21st century 
mortality in six smaller cohorts of US smokers now 
suggest, in aggregate, similar hazards from smoking 
and beneﬁ ts of stopping,20,21 as does a recent study in 
Japanese men and women.22 Women who were smoking 
at baseline and still smoking at the 3-year resurvey had 
triple the overall mortality of never-smokers, despite 
many having subsequently reduced their risks by 
stopping after that resurvey. Hence, if none had stopped 
then the all-cause smoker versus never-smoker mortality 
ratio would have been somewhat greater than 3.
Although a little of this excess would have been non-
causal, an overall mortality ratio somewhat greater than 
3 implies that continued smoking would actually cause 
smokers to have roughly triple the mortality rate of 
otherwise similar never-smokers of the same age. Hence, 
among continuing smokers in this population who died, 
two-thirds died at the age they did because smoking 
caused their death. This is despite large declines in 
machine-measured tar yields in recent decades, with 
women in the UK smoking cigarettes containing less 
than 10 mg of tar per cigarette, on average, throughout 
this study.2 Low-tar cigarettes are not low-risk cigarettes, 
and the Million Women Study shows that more than half 
of those who smoke them will eventually be killed by 
them, unless they stop smoking in time to avoid this.
Most women were recruited at ages 50–65 years and 
were then followed for 9–15 years, so this study was of 
mortality at ages 50–80 years (but mainly 55–74 years). 
Within this range, the smoker versus never-smoker 
mortality ratio was roughly independent of age, so the 
conclusion that smoking triples mortality rates can be 
applied as a reasonable approximation not only through-
out the age range 50–80 years but also at somewhat 
younger ages (and, perhaps, somewhat older ages).
The absolute death rates in women included in these 
analyses are lower than the UK average, partly because 
those with various previous illnesses were excluded, and 
also because participants were recruited through a 
national screening programme, and so were relatively 
healthy volunteers. The absolute eﬀ ects at current UK 
death rates of a three-fold diﬀ erence in age-speciﬁ c 
mortality rates can, however, be illustrated by comparing 
the probabilities of survival from ages 35–80 years that 
would be seen in a hypothetical population in which 
non-smokers have exactly two-thirds of the UK 
2010 age-speciﬁ c female mortality rates and smokers 
have three times the rates of non-smokers (ﬁ gure 5). (We 
note that if, at each age, 75% are at low risk and have 
two-thirds of the UK rates and the remainder have rates 
three times as great, the overall mortality rates would 
match the overall UK rates.)
In ﬁ gure 5, the smokers lose about 11 years of lifespan. 
The probabilities of death before age 70 years are 24% for 
smokers and 9% for never-smokers (absolute diﬀ erence 
15%), and the probabilities of death before age 80 years 
are 53% and 22% (absolute diﬀ erence 31%). These prob-
abilities of female death before age 80 years in smokers 
and non-smokers are similar to the corresponding 
probabilities of male death before age 70 years for British 
doctors born in 1900–30.5 Although the relative risks 
seem to be more extreme for women than for men, the 
eventual absolute excess risks seem similar for male and 
female smokers. 
Because the absolute hazards of prolonged smoking 
are sub stantial, so too are the absolute beneﬁ ts of 
cessation. Even cessation at about 50 years of age 
avoids at least two-thirds of the continuing smoker’s 
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Figure 5: All-cause mortality: Illustration of the eﬀ ects of a 3-fold diﬀ erence in annual death rates on 
mortality from age 35 years to age 80 years
This hypothetical example takes age-speciﬁ c death rates in non-smokers to be two-thirds of the UK 2010 female 
rates and those in smokers to be three times as great. NB In a population where at each age 75% have two-thirds of 
the UK rates and 25% have rates three times as great, the overall death rates in that population would match the 
UK rates. The horizontal arrows show that the non-smoker rates of death at ages 70 or 80 years are experienced 
11 years earlier by smokers, suggesting an 11-year loss of lifespan.
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excess mortality in later middle age. The beneﬁ ts are, 
however, con siderably greater for those who stop much 
earlier (panel).
Smokers who stop at about 40 years of age avoid about 
90% of the excess hazard among continuing smokers, 
whereas those who stop at about 30 years of age avoid 
about 97% of it. Hence, stopping well before age 40 years 
would avoid well over 90% of the excess hazard in 
continuing smokers, and stopping well before age 
30 years would avoid well over 97% of it.
This does not, however, mean that it is safe to smoke 
until age 40 years and then stop, for women who do so 
have throughout the next few decades a mortality rate 
1·2 times that of never-smokers. This is a substantial 
excess risk, causing one in six of the deaths among these 
ex-smokers. The excess risk is, however, ten times as 
great in women who smoke until age 40 years and do not 
stop, for at any given age their mortality rate is three 
times that of never-smokers.
In every country, the full hazards of smoking can be 
observed directly only when the ﬁ rst generation to smoke 
cigarettes throughout adult life has reached old age. In 
such populations, it is also possible to observe directly 
the substantial beneﬁ ts of early cessation. However, in 
any population in the world in which young adults smoke 
cigarettes, the beneﬁ ts of early cessation will be sub-
stantial, not necessarily in comparison with the current 
hazards noted among smokers in that population, but in 
comparison with their own eventual risks if those young 
smokers were to continue.23
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Panel: Research in context
Systematic review
There have already been many reviews17–19 of previous studies 
of mortality associated with smoking in women. Although we 
routinely undertake online searches of such studies, we did 
not undertake another review of their results. For, the hazards 
among smokers in later middle age depend strongly not only 
on their recent smoking patterns, but also on their patterns of 
smoking in early adult life,4 so previous studies could not yet 
observe directly the full eventual hazards of smoking or the 
full beneﬁ ts of cessation among women. These can ﬁ rst be 
seen only as the generation born around 1940 in countries 
such as the UK and USA is followed into the 21st century, as 
this is the ﬁ rst generation in which many women began to 
smoke substantial numbers of cigarettes in early adult life.  
Interpretation
A major aim of the Million Women Study was to assess directly 
the full eventual hazards of prolonged smoking and the full 
beneﬁ ts of stopping at various ages. Women who have smoked 
cigarettes throughout adult life have as a result three times the 
overall mortality rate of otherwise similar women who have 
never smoked, or who stopped well before middle age. 
Stopping before 40 years of age, and preferably well before, 
avoids more than 90% of this excess mortality; stopping before 
30 years of age avoids more than 97% of it. Nevertheless, the 
residual hazards among those who smoke until age 40 years 
and then stop are substantial as decades later, they still have 
1·2 times the mortality rate of never-smokers. Reports of 
21st century mortality among women in the USA are currently 
in press elsewhere,20–21 corroborating our ﬁ ndings about the 
hazards of smoking and beneﬁ ts of stopping among women in 
the UK. In both countries, if women smoke like men, they die 
like men—but, stopping early enough gains 10 extra years of 
life expectancy for women or men.
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